SGOL2 promotes prostate cancer progression by inhibiting RAB1A ubiquitination

Prostate cancer is the most prevalent genitourinary malignant cancer in men worldwide. Patients with prostate cancer who progress to castration-resistant prostate cancer (CRPC) or metastatic CRPC have significantly poorer survival. Advanced prostate cancer is a clinical challenge due to the lack of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Tingting, He, Dongwei, Zhang, Xiaokuan, Guo, Xiaojin, Li, Zijie, Zhang, Aili, Fan, Bo, Wang, Zhiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831743/
https://www.ncbi.nlm.nih.gov/pubmed/36566018
http://dx.doi.org/10.18632/aging.204443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831743/
https://www.ncbi.nlm.nih.gov/pubmed/36566018
http://dx.doi.org/10.18632/aging.204443

Ejemplares similares